Please fill out the contact form below and we will reply as soon as possible.
Important Notice Regarding BC Pharmacare Coverage Buprenorphine/naloxone, extended-release subcutaneous buprenorphine (Sublocade), commercially available methadone (Methadose and Metadol-D), and slow-release...
February 6th, 2025 34 views 0 likes
Buprenorphine is a partial opioid agonist available as both a monoproduct and a combined formulation of buprenorphine and naloxone. The...
February 6th, 2025 38 views 0 likes
A substantial body of evidence has shown methadone to be significantly more effective than non-pharmacological outpatient treatment approaches in terms...
February 6th, 2025 40 views 0 likes
Slow-release oral morphine (SROM) is widely used for pain management, but there is also a growing evidence base for its...
February 6th, 2025 35 views 0 likes
Treatment retention Data regarding comparative treatment retention among the 3 oral OAT medications is mixed. For example, a 2021 meta-analysis...
February 6th, 2025 52 views 0 likes
Given the high rates of hospitalization among individuals with OUD, inpatient settings present a significant opportunity to engage individuals in...
February 6th, 2025 37 views 0 likes
Given the significant pharmacologic and pharmacokinetic differences among OAT medications, practice standards for take-home dosing have been informed by each...
February 6th, 2025 36 views 0 likes
Individuals with opioid use disorder may face a number of barriers to initiation of, and retention in, oral OAT, including...
February 6th, 2025 32 views 0 likes
Retention in OAT is associated with substantial reduction in all-cause and overdose mortality,111 whereas abundant observational evidence has associated discontinuation...
February 6th, 2025 30 views 0 likes
Based on a review of evidence supporting the safety and efficacy of OAT medications, this guideline recommends the following: Recommendation...